RAD 51 Gene 135G/C polymorphism and the risk of four types of common cancers: a meta-analysis

Diagnostic Pathology

Table 3 Total and stratified analysis of the RAD51 135G/C polymorphism on risk of the four cancers

Variables	No.^a	Case/Control	GG vs. CC			GC vs. CC			GG+GC vs. CC			GG vs. GC+CC
			OR(95% CI)	P^b	P	OR(95% CI)	P^b	P	OR(95% CI)	P^b	P	OR(95% CI)	P^b	P
Total cancer types	22	6836/8507	0.83(0.43–1.59)	0.00^c	0.57	0.90(0.39–2.08)	0.00^c	0.81	0.82(0.39–1.73)	0.00^c	0.60	0.84(0.69–1.02)	0.00^c	0.08
SCCHN	4	1237/1340	2.46(1.08–5.61)	0.50	0.03	2.20(0.30–16.22)	0.02	0.44	2.50(0.76–8.28)	0.25	0.13	0.84(0.40–1.75)	0.00^c	0.64
CC	4	753/720	0.92(0.08–10.55)	0.00^c	0.95	0.65(0.05–8.08)	0.00^c	0.74	0.79(0.06–10.16)	0.00^c	0.85	1.12(0.53–2.35)	0.00^c	0.77
OC	5	2001/2420	0.42(0.10–1.78)	0.0007	0.24	0.41(0.06–2.67)	0.00^c	0.35	0.40(0.07–2.18)	0.00^c	0.29	0.80(0.62–1.03)	0.07	0.09
AL	9	2845/4027	0.82(0.49–1.39)	0.26	0.47	1.00(0.59–2.08)	0.29	0.99	0.85(0.50–1.44)	0.25	0.60	0.82(0.63–1.07)	0.002	0.14
Source of controls
HCC	13	3409/4126	0.77(0.30–1.98)	0.00^c	0.58	0.79(0.24–2.60)	0.00^c	0.70	0.74(0.26–2.13)	0.00^c	0.58	0.82(0.60–1.12)	0.00^c	0.20
PCC	9	3427/4381	0.93(0.53–1.62)	0.87	0.79	1.14(0.64–2.02)	0.87	0.66	0.95(0.54–1.67)	0.88	0.87	0.88(0.71–1.09)	0.01	0.25
Ethnicity
Asian	3	1170/1866	0.92(0.27–3.19)	0.01	0.90	0.98(0.28–3.40)	0.01	0.97	0.94(0.27–3.26)	0.009	0.92	0.94(0.77–1.14)	0.64	0.52
Caucasian	18	5616/6611	0.80(0.36–1.79)	0.00^c	0.59	0.86(0.31–2.38)	0.00^c	0.77	0.79(0.32–1.95)	0.00^c	0.61	0.83(0.65–1.05)	0.00^c	0.13
African	1	50/30	0.75(0.06–8.70)		0.82	1.50(0.10–23.07)		0.77	0.83(0.07–9.54)		0.88	0.55(0.16–1.90)		0.34

^aNumber of studies.
^bP value of Q-test for heterogeneity test.
^cFixed-effects model was used when P value for heterogeneity test <0.10, otherwise, random-effects model was used.
SCCHN: squamous cell carcinoma of the head and neck; CC: colorectal cancer; OC: ovarian cancer; AL: acute leukaemia.

ISSN: 1746-1596